{
    "organizations": [],
    "uuid": "cf5135a353c3f4bb5dd30dc137bd451bee11380e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-entasis-therapeutics-and-zai-lab-a/brief-entasis-therapeutics-and-zai-lab-announce-exclusive-license-agreement-in-asia-pacific-and-global-strategic-development-collaboration-for-etx2514-idUSFWN1S20RM",
    "ord_in_thread": 0,
    "title": "BRIEF-Entasis Therapeutics And Zai Lab Announce Exclusive License Agreement In Asia-Pacific And Global Strategic Development Collaboration For ETX2514",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - Zai Lab Ltd:\n* ENTASIS THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT IN ASIA-PACIFIC AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION FOR ETX2514\n* ZAI LAB LTD - COLLABORATION WILL FACILITATE ENROLLMENT OF GLOBAL PHASE 3 TRIAL OF ETX2514 IN COMBINATION WITH SULBACTAM\n* ZAI LAB LTD - ZAI LAB WILL MANAGE PORTION OF PHASE 3 TRIAL CONDUCTED IN CHINA\n* ZAI LAB LTD - ETX2514SUL IS CURRENTLY IN PHASE 2 DEVELOPMENT WITH PLANS TO MOVE INTO GLOBAL PHASE 3 CLINICAL TRIALS IN Q1 OF 2019\n* ZAI LAB LTD - ENTASIS AND CO HAVE AN OPTION TO COLLABORATE ON DEVELOPMENT, COMMERCIALIZATION OF ETX2514 IN COMBINATION WITH OTHER ACTIVE INGREDIENTS\n* ZAI LAB - ENTASIS WILL RECEIVE A $5 MILLION UPFRONT PAYMENT, ELIGIBLE FOR UP TO $91 MILLION IN MILESTONE PAYMENTS RELATED TO ETX2514SUL, OTHER COMBINATIONS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-25T20:08:00.000+03:00",
    "crawled": "2018-04-26T20:21:40.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "zai",
        "lab",
        "ltd",
        "entasis",
        "therapeutic",
        "zai",
        "lab",
        "announce",
        "exclusive",
        "license",
        "agreement",
        "global",
        "strategic",
        "development",
        "collaboration",
        "etx2514",
        "zai",
        "lab",
        "ltd",
        "collaboration",
        "facilitate",
        "enrollment",
        "global",
        "phase",
        "trial",
        "etx2514",
        "combination",
        "sulbactam",
        "zai",
        "lab",
        "ltd",
        "zai",
        "lab",
        "manage",
        "portion",
        "phase",
        "trial",
        "conducted",
        "china",
        "zai",
        "lab",
        "ltd",
        "etx2514sul",
        "currently",
        "phase",
        "development",
        "plan",
        "move",
        "global",
        "phase",
        "clinical",
        "trial",
        "q1",
        "zai",
        "lab",
        "ltd",
        "entasis",
        "co",
        "option",
        "collaborate",
        "development",
        "commercialization",
        "etx2514",
        "combination",
        "active",
        "ingredient",
        "zai",
        "lab",
        "entasis",
        "receive",
        "million",
        "upfront",
        "payment",
        "eligible",
        "million",
        "milestone",
        "payment",
        "related",
        "etx2514sul",
        "combination",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}